MoonLake Immunotherapeutics Investors Face December 15 Legal Deadline
New York, Saturday, 6 December 2025.
Investors in MoonLake Immunotherapeutics with losses over $100,000 are urged to secure legal counsel by December 15 due to a class action lawsuit alleging misleading statements about drug efficacy.
Legal Challenges and Implications for MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (NASDAQ: MLTX) is currently embroiled in a class action lawsuit, with investors being urged to seek legal counsel by December 15, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its drug candidate, sonelokimab (SLK). Specifically, it is claimed that MoonLake overstated the clinical benefits of SLK compared to traditional monoclonal antibodies, which has resulted in significant financial losses for investors [1][2].
Impact on Investor Confidence and Market Stability
The allegations against MoonLake have raised critical concerns about investor confidence and the stability of the biotechnology market. The lawsuit contends that misleading statements about SLK’s ability to penetrate tissues and confer clinical benefits led to a nearly 90% loss in stock value during the class period from March 10, 2024, to September 29, 2025 [3][4]. As the December 15 deadline approaches, stakeholders are advised to remain vigilant and informed about the developments in this legal battle to mitigate potential financial repercussions.
Rosen Law Firm and Bernstein Liebhard LLP’s Role
Two prominent law firms, Rosen Law Firm and Bernstein Liebhard LLP, have taken center stage in this legal proceeding. Both firms have a strong track record in securities class actions and are encouraging affected investors to participate in the lawsuit. While Rosen Law Firm emphasizes the importance of securing legal rights before the deadline, Bernstein Liebhard LLP highlights its extensive experience in recovering significant settlements for its clients [1][5][6].
Next Steps for Investors
For investors who purchased MoonLake stock within the specified class period and have incurred losses exceeding $100,000, immediate action is recommended. Joining the class action lawsuit can provide a pathway to potential recovery of losses. Investors can contact the involved law firms via their respective websites or provided contact details to understand the process and implications of participating as a lead plaintiff [2][6].